World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 18 April 2017
Main ID:  ChiCTR-OPN-16010028
Date of registration: 2016-11-23
Prospective Registration: No
Primary sponsor: Yancheng Third People's Hospital
Public title: Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria
Scientific title: Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria
Date of first enrolment: 2011-01-01
Target sample size: Prednisone (PRE) group:10;conventional-dose TW (CTW) group:10;double-dose TW (DTW) group:10;
Recruitment status: Completed
URL:  http://www.chictr.org.cn/showproj.aspx?proj=16968
Study type:  Observational study
Study design:  Non randomized control  
Phase:  Post-market
Countries of recruitment
Contacts
Name: Li-na Zhou   
Address:  301 Middle Yanchang Road, Shanghai
Telephone: +86 15901989527
Email: wang.zhen@tongji.edu.cn
Affiliation:  Shanghai Tenth People's Hospital, Tongji University School of Medicine
Name: Zhen Wang   
Address:  301 Middle Yanchang Road, Shanghai
Telephone: +86 15901989527
Email: wang.zhen@tongji.edu.cn
Affiliation:  Shanghai Tenth People's Hospital, Tongji University School of Medicine
Key inclusion & exclusion criteria
Inclusion criteria: IgAN and heavy proteinuria (=3.5 g/24 h)
Exclusion criteria: Patients with other causes of IgA-positive glomerular staining, such as Henoch-Schnlein nephritis and lupus nephritis, were excluded.
The coincidence of IgAN and minimal change disease confirmed by electron microscopy was also excluded from the study.


Age minimum: 21
Age maximum: 54
Gender: Both
Health Condition(s) or Problem(s) studied
IgA nephropathy
Intervention(s)
Prednisone (PRE) group:1mg/kg prednisone once daily;conventional-dose TW (CTW) group:60 mg TW daily;double-dose TW (DTW) group:?????120mg;
Primary Outcome(s)
proteinuria;
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
the Natural Science Foundation of China
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history